Table 2.
Subgroup analysis of mPFS.
| Patients with event, n (%) | mPFS (95% CI) | |
|---|---|---|
| BRCA mutation status | ||
| BRCAm | 56 (25.0) | 21.2 (16.4–24.9) |
| Germline BRCAm | 48 (21.4) | 21.4 (16.5–24.9) |
| Somatic BRCAm | 8 (3.6) | 16.1 (5.9–NE) |
| BRCAwt | 82 (36.6) | 11.0 (8.3–15.8) |
| HRR mutation status | ||
| HRRm | 69 (30.8) | 18.3 (14.5–24.1) |
| HRRwt | 69 (30.8) | 13.3 (8.3–16.5) |
| Age group at first dose | ||
| <65 years | 117 (52.2) | 15.8 (11.0–18.2) |
|
22 (9.8) | 19.7 (11.1–22.2) |
| Last line of previous anticancer therapy | ||
| 2nd line | 82 (36.6) | 18.0 (15.8–22.1) |
| 3rd line | 38 (17.0) | 8.8 (6.8–13.9) |
| 4th line and beyond | 19 (8.5) | 13.3 (5.5–20.1) |
| Time to disease progression on second to last platinum-based chemotherapy | ||
| >12 months | 70 (31.3) | 20.9 (16.2–24.1) |
| 6–12 months | 67 (29.9) | 9.3 (8.3–14.1) |
| Best response | ||
| CR | 43 (19.2) | 19.7 (15.8–22.2) |
| PR | 96 (42.9) | 13.9 (11.0–16.6) |
Abbreviations: CI, confidence interval; m, mutation; CR, complete response; HRR, homologous recombination repair; NE, not evaluable; PR, partial response; wt, wild type.